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PRACTICE VARIATION IN SUPPORTIVE CARE IN HEMATOPOIETIC CELL
TRANSPLANTATION
Lee, S.J.1, Eapen, M.1, Soiffer, R.J.1, McCarthy, P.L.1, Loberiza, F.1,
Kernan, N.A.1, Jagasia, M.1, Davies, S.1, Artz, A.1, Joffe, S.1 1Center
for International Blood and Marrow Transplant Research, Milwaukee,
WI.
Background: No studies describe individual physician practices
in hematopoietic stem cell transplantation (HCT). We conducted
an international Internet-based survey of physicians to explore the
spectrum of supportive care practices in HCT. Methods: Ques-
tions addressed pre-HCT patient and donor testing, infectious
disease prophylaxis and treatment, and protective isolation recom-
mendations after HCT. Response options were closed-ended of-
fering several management approaches. The response rate was
526/627 (84%) of eligible physicians who conﬁrmed receipt of the
invitation, or 526/1823 (29%) of all invitations. Respondents were
clinically active with a median of 2.5 days in clinic and 4 months
inpatient service (60% clinical effort). 57% practiced in the U.S.
Results: Measurement of cardiac and pulmonary function and
requirement for signed informed consent before HCT was almost
universal (90%). Though use of antifungal prophylaxis was rou-
tine (90-96%), other measures such as myeloid growth factors
(45-79%), antibacterial prophylaxis (50-79%) and ursodeoxycholic
acid (22-41%) were less common. Approximately half used a single
agent broad spectrum antibiotic for empiric treatment of febrile
neutropenia, while a third used combination therapy that included
an aminoglycoside. While 94-97% recommended handwashing
and 73-86% used hepa-ﬁltration,  50% used other isolation
procedures during hospitalization (e.g., masks, gloves, gowns).
Recommendations for protective isolation after HCT, such as
visitors in the home, use of masks and/or gloves in public, eating
out, going to indoor public places (median  100 days) and return
to work/school (median 3-6 months) were variable, but stricter
policies were predicted by allogeneic/myeloablative and pediatric
versus adult practice. Other physician characteristics, such as US
vs. non-US and shorter time since completion of fellowship also
predicted stricter isolation recommendations and appear less bio-
logically justiﬁable. Conclusions: Our results demonstrate the
heterogeneity of supportive care practices in HCT. For most
practices, little data exist to favor one approach over another.
Where data do exist, as for antifungal prophylaxis and ursodeoxy-
cholic acid during myeloablative procedures, uptake into standard
practice is variable. Although the relative contribution of support-
ive care management to overall success of HCT is unknown, the
diversity of supportive care approaches suggests randomized stud-
ies are possible.
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PREVALENCE OF FALLS AND SUBSEQUENT PATTERNS OF INJURY IN A
PEDIATRIC ONCOLOGY HOSPITAL
Mattox, S.1, Dycus, P.1, Hale, G.A.1 1St. Jude Children’s Research
Hospital, Memphis, TN.
Falls are a signiﬁcant cause of morbidity in hospitalized patients,
but are primarily documented in older adults. Little data is pub-
lished regarding falls in children and adolescents. Pediatric patients
are at risk for falling because of neurologic disease, medication-
related causes, post-operative sequelae, and as part of normal
childhood development. We now report the experience with inpa-
tient and outpatient falls at a pediatric tertiary care facility for
patients with catastrophic diseases. Data was collected through the
hospital incident reporting system from 4/1/2000, to 2/28/2006.
Observation was done by the employee who witnessed the event.
193 patients fell 231 times during this time period: 43 in outpatient
areas and 150 while hospitalized. The median age was 7 years
(range, 6 months to 23 years) and 111 were male. Trauma to the
head or facial area occurred in 41% of the patients. Areas that most
outpatient falls occurred were clinic exam rooms (16), hallways
(15), waiting areas (8) and the Rehabilitation Department (6).
Three occurrences happened while patients were being weighed on
scales. Sixty-four inpatient falls occurred in patient’s room. Ap-
proximately 33% of the inpatient falls were either in the patient’s
bathroom or related to the patient ambulating to or from the
bathroom. Diagnoses of patients included, 79 leukemia/lymphoma,
65 solid tumor, 38 brain tumor and 11 non-malignant patients. 14
patients had undergone autologous HSCT and 27 allogeneic
HSCT (9 MSD, 7 MUD, 11 MMFM). The total number of falls
was 54. Of the HSCT patients who fell, they were a median of 93
days post-HSCT; 16 had acute or chronic GVHD. Pediatric falls
occur commonly in all areas of the hospital, but are more common
on inpatient units. Institutional measures to prospectively identify
pediatric patients at risk for falling are needed in order to initiate
falls prevention programs in children’s hospitals.
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THE SIGNIFICANCE OF PALIFERMIN (KEPIVANCE) IN REDUCTION OF
ORAL MUCOSITIS (OM) INCIDENCE AND ACUTE GRAFT VERSUS HOST
DISEASE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDER-
GOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Nasilowska-Adamska, B.1, Rzepecki, P.2, Manko, J.3, Czyz, A.4,
Markiewicz, M.5, Fedorowicz, I.6, Tomaszewska, A.7,
Piatkowska-Jakubas, B.8, Wrzesien-Kus, A.9, Bieniaszewska, M.10,
Duda, D.11, Halaburda, K.1, Szczepinski, A.1, Lange, A.11,
Hellman, A.10, Robak, T.9, Skotnicki, A.8, Jedrzejczak, W.W.7,
Walewski, J.6, Holowiecki, J.5, Komarnicki, M.4, Dmoszynska, A.3,
Warzocha, K.1, Marianska, B.1 1Institute of Hematology and Blood
Transfusion, Warsaw, Poland; 2Military Medical Academy, Warsaw,
Poland; 3Medical University, Lublin, Poland; 4K. Marcinkowski Uni-
versity of Medical Science, Poznan, Poland; 5Silesian Medical Academy,
Katowice, Poland; 6M. Sklodowska-Curie Memorial Institute, Warsaw,
Poland; 7Medical University, Warsaw, Poland; 8Collegium Medicum of
Jagiellonian University, Krakow, Poland; 9Medical University, Lodz,
Poland; 10Medical University, Gdansk, Poland; 11Lower Silesian Centre
for Cellular Transplantation, Wroclaw, Poland.
Oral mucositis is a frequent complication of myeloablative
therapy and HSCT with no effective treatment. We tested the
ability of palifermin (rHuKGF) to reduce the incidence, dura-
tion, and severity of OM induced by high-dose chemotherapy
followed by HSCT in patients (pts) with hematologic malignan-
cies and evaluated the need for analgesics and parenteral nutri-
tion administered because of OM, incidence of febrile neutro-
penia (38°C), and severe infections. Palifermin inﬂuence on
hematopoietic recovery, acute graft vs host disease (aGvHD),
and duration of hospitalization after HSCT were also assessed.
106 pts with hematologic malignancies were enrolled; 53 (50%)
received palifermin (60 mcg/kg/d) for 3 consecutive days before
and after conditioning therapy. Median ages of the palifermin
and historical control groups were 37 yrs (range, 19–58) and
36.1 yrs (range, 18–64), respectively. 30 (5%) autologous and 23
(43%) allogeneic HSCT were done in the palifermin group and
28 (53%) and 25 (47%) in the control group. OM was graded
daily after autoHSCT according to the WHO scale. Incidence
of grade 1-4 OM was 58% for palifermin and 94% for control.
Grade 3-4 incidence was 13% for palifermin and 43% for
control (p0.001). Among all pts, median duration of OM was
4 d (range, 0–16) for palifermin and 9 d (range, 0–28) for
control (p0.001). Compared with control, palifermin was as-
sociated with signiﬁcant reductions in use of analgesics (32% vs
76%), opioid analgesics (24% vs 64%), and parenteral nutrition
(11% vs 45%) (p0.001). aGvHD incidence was reduced for the
palifermin group (25% vs 50%; p0.03), especially the gastro-
intestinal form (8% vs 29%; p0.03 ). No signiﬁcant differences
in febrile neutropenia and severe infections incidences were
observed. Palifermin did not impair reconstitution of the hema-
topoietic system (Table) and did not signiﬁcantly reduce the
median duration of hospitalization (24.5 d, range 10–60 for
palifermin vs 28 d, range 10–83 for control). The drug was
generally well tolerated. Adverse events included rash, pruritus,
erythema, generalized edema, mouth/tongue thickness and dis-
coloration, taste alteration, and proteinuria. Palifermin signiﬁ-
cantly reduced the incidence, severity, and duration of OM
without a negative effect on engraftment in pts with hemato-
logic malignancies after HSCT. The incidence of aGvHD also
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